Keros Therapeutics announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension. As a result, Keros expects to complete enrollment by the end of September and present topline data in the second quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
- Keros Therapeutics CEO to Speak at Major Healthcare Conferences
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
- Keros Therapeutics director sells $11.0M in common stock
- Keros Therapeutics participates in a conference call with Cantor Fitzgerald